Luxcel Biosciences announced they have entered a strategic partnership to co‐market and provide new assay technologies for preclinical drug safety services.
Research results published in the BMJ suggest that post-marketing studies funded by drug companies may be too small to detect rare side effects, as reported in Yahoo!Finance.